Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country
Main Author: | |
---|---|
Publication Date: | 2020 |
Other Authors: | , , , |
Format: | preprint |
Language: | spa |
Source: | SciELO Preprints |
Download full: | https://preprints.scielo.org/index.php/scielo/preprint/view/545 |
Summary: | Currently, there is no available vaccine or specific medication against Coronavirus Disease 2019 (COVID-19). The treatment is fundamentally based on supportive measures. In recent weeks, in various parts of the world, including our country, there have been flexibilities for the scientific community to conduct clinical trials with potentially useful therapies, such as the case of convalescent plasma transfusion (CPT) of patients with COVID-19. A MEDLINE search of studies on convalescent plasma and COVID-19, SARS or MERS was performed. Studies on the clinical efficacy of this treatment in diseases caused by other coronaviruses (SARS-CoV and MERS-CoV) showed clinical improvement, increased neutralizing antibodies, decreased mortality and the absence of adverse events during and after treatment. In the case of COVID-19, 6 studies were found of the use of this treatment in patients with severe COVID-19 (in mechanical ventilation and with acute respiratory distress syndrome). Although there are limitations in the methodology, number of patients and protocols for the analysis of convalescent plasma from donors, the patients who received CPT showed clinical improvement, improvement in ventilatory patterns, resolution of lung lesions, decreased mortality, improvement in laboratory parameters, increased neutralizing antibodies, decreased viral load and absence of adverse events. We also present a protocol for carrying out TPC and proposals for its implementation and use in our country. |
id |
SCI-1_abc82abe7dbd3af2da2ebde5cf1a3d5c |
---|---|
oai_identifier_str |
oai:ops.preprints.scielo.org:preprint/545 |
network_acronym_str |
SCI-1 |
network_name_str |
SciELO Preprints |
repository_id_str |
|
spelling |
Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our countryTransfusión de plasma convaleciente de pacientes con COVID-19: Propuesta de la Sociedad Peruana de Inmunología y la Asociación Médica Peruana de Patología Clínica para su implementación en nuestro paísMERSPerúSARS-Cov-2SARSCOVID-19COVID-19MERSPeruConvalescent plasmaSARS-CoV-2SARS VirusCurrently, there is no available vaccine or specific medication against Coronavirus Disease 2019 (COVID-19). The treatment is fundamentally based on supportive measures. In recent weeks, in various parts of the world, including our country, there have been flexibilities for the scientific community to conduct clinical trials with potentially useful therapies, such as the case of convalescent plasma transfusion (CPT) of patients with COVID-19. A MEDLINE search of studies on convalescent plasma and COVID-19, SARS or MERS was performed. Studies on the clinical efficacy of this treatment in diseases caused by other coronaviruses (SARS-CoV and MERS-CoV) showed clinical improvement, increased neutralizing antibodies, decreased mortality and the absence of adverse events during and after treatment. In the case of COVID-19, 6 studies were found of the use of this treatment in patients with severe COVID-19 (in mechanical ventilation and with acute respiratory distress syndrome). Although there are limitations in the methodology, number of patients and protocols for the analysis of convalescent plasma from donors, the patients who received CPT showed clinical improvement, improvement in ventilatory patterns, resolution of lung lesions, decreased mortality, improvement in laboratory parameters, increased neutralizing antibodies, decreased viral load and absence of adverse events. We also present a protocol for carrying out TPC and proposals for its implementation and use in our country.Actualmente no existe vacuna disponible ni medicación específica contra la enfermedad de Coronavirus 2019 (COVID-19). El tratamiento se basa fundamentalmente en medidas de soporte. En las últimas semanas, en varias partes del mundo, incluido nuestro país, se han dado flexibilidades para que la comunidad científica conduzca ensayos clínicos con terapias de potencial utilidad, como es el caso de la transfusión de plasma convaleciente (TPC) de pacientes con COVID-19. Se realizó una búsqueda en MEDLINE de estudios sobre plasma convaleciente y COVID-19, SARS o MERS. Los estudios sobre la eficacia clínica de este tratamiento en enfermedades causadas por otros coronavirus (SARS-CoV y MERS-CoV) evidenciaron mejoría clínica, aumento de anticuerpos neutralizantes, disminución de mortalidad y ausencia de eventos adversos durante y después del tratamiento. En el caso del COVID-19, se encontraron 6 estudios del uso de este tratamiento en pacientes con COVID-19 severo (en ventilación mecánica y con síndrome de distrés respiratorio agudo). Aunque existen limitaciones en la metodología, número de pacientes y protocolos para el análisis del plasma convaleciente de los donantes, los pacientes que recibieron TPC evidenciaron mejoría clínica, mejoría de patrones ventilatorios, resolución de lesiones pulmonares, disminución de mortalidad, mejoría de parámetros laboratoriales, aumento de anticuerpos neutralizantes, disminución de carga viral y ausencia de eventos adversos. Presentamos además un protocolo de realización de TPC y propuestas para su implementación y uso en nuestro país.SciELO PreprintsSciELO PreprintsSciELO Preprints2020-05-26info:eu-repo/semantics/preprintinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://preprints.scielo.org/index.php/scielo/preprint/view/54510.1590/SciELOPreprints.545spahttps://preprints.scielo.org/index.php/scielo/article/view/545/691Copyright (c) 2020 Cesar Alberto Galvan, Crhistian Gabriel Toribio-Dionicio, Marco Antonio Álvarez-Ángeles, Óscar Daniel Alama-Bazán, Luis Alberto Antonio Sánchez-Ramírezhttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessGalvan, Cesar AlbertoToribio-Dionicio, Crhistian GabrielÁlvarez-Ángeles, Marco AntonioAlama-Bazán, Óscar DanielSánchez-Ramírez, Luis Alberto Antonioreponame:SciELO Preprintsinstname:SciELOinstacron:SCI2020-05-22T01:59:20Zoai:ops.preprints.scielo.org:preprint/545Servidor de preprintshttps://preprints.scielo.org/index.php/scieloONGhttps://preprints.scielo.org/index.php/scielo/oaiscielo.submission@scielo.orgopendoar:2020-05-22T01:59:20SciELO Preprints - SciELOfalse |
dc.title.none.fl_str_mv |
Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country Transfusión de plasma convaleciente de pacientes con COVID-19: Propuesta de la Sociedad Peruana de Inmunología y la Asociación Médica Peruana de Patología Clínica para su implementación en nuestro país |
title |
Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country |
spellingShingle |
Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country Galvan, Cesar Alberto MERS Perú SARS-Cov-2 SARS COVID-19 COVID-19 MERS Peru Convalescent plasma SARS-CoV-2 SARS Virus |
title_short |
Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country |
title_full |
Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country |
title_fullStr |
Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country |
title_full_unstemmed |
Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country |
title_sort |
Convalescent plasma transfusion of COVID-19 patients: Proposal from the Peruvian Immunology Society and the Peruvian Medical Association of Clinical Pathology for its implementation in our country |
author |
Galvan, Cesar Alberto |
author_facet |
Galvan, Cesar Alberto Toribio-Dionicio, Crhistian Gabriel Álvarez-Ángeles, Marco Antonio Alama-Bazán, Óscar Daniel Sánchez-Ramírez, Luis Alberto Antonio |
author_role |
author |
author2 |
Toribio-Dionicio, Crhistian Gabriel Álvarez-Ángeles, Marco Antonio Alama-Bazán, Óscar Daniel Sánchez-Ramírez, Luis Alberto Antonio |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Galvan, Cesar Alberto Toribio-Dionicio, Crhistian Gabriel Álvarez-Ángeles, Marco Antonio Alama-Bazán, Óscar Daniel Sánchez-Ramírez, Luis Alberto Antonio |
dc.subject.por.fl_str_mv |
MERS Perú SARS-Cov-2 SARS COVID-19 COVID-19 MERS Peru Convalescent plasma SARS-CoV-2 SARS Virus |
topic |
MERS Perú SARS-Cov-2 SARS COVID-19 COVID-19 MERS Peru Convalescent plasma SARS-CoV-2 SARS Virus |
description |
Currently, there is no available vaccine or specific medication against Coronavirus Disease 2019 (COVID-19). The treatment is fundamentally based on supportive measures. In recent weeks, in various parts of the world, including our country, there have been flexibilities for the scientific community to conduct clinical trials with potentially useful therapies, such as the case of convalescent plasma transfusion (CPT) of patients with COVID-19. A MEDLINE search of studies on convalescent plasma and COVID-19, SARS or MERS was performed. Studies on the clinical efficacy of this treatment in diseases caused by other coronaviruses (SARS-CoV and MERS-CoV) showed clinical improvement, increased neutralizing antibodies, decreased mortality and the absence of adverse events during and after treatment. In the case of COVID-19, 6 studies were found of the use of this treatment in patients with severe COVID-19 (in mechanical ventilation and with acute respiratory distress syndrome). Although there are limitations in the methodology, number of patients and protocols for the analysis of convalescent plasma from donors, the patients who received CPT showed clinical improvement, improvement in ventilatory patterns, resolution of lung lesions, decreased mortality, improvement in laboratory parameters, increased neutralizing antibodies, decreased viral load and absence of adverse events. We also present a protocol for carrying out TPC and proposals for its implementation and use in our country. |
publishDate |
2020 |
dc.date.none.fl_str_mv |
2020-05-26 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/preprint info:eu-repo/semantics/publishedVersion |
format |
preprint |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://preprints.scielo.org/index.php/scielo/preprint/view/545 10.1590/SciELOPreprints.545 |
url |
https://preprints.scielo.org/index.php/scielo/preprint/view/545 |
identifier_str_mv |
10.1590/SciELOPreprints.545 |
dc.language.iso.fl_str_mv |
spa |
language |
spa |
dc.relation.none.fl_str_mv |
https://preprints.scielo.org/index.php/scielo/article/view/545/691 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
SciELO Preprints SciELO Preprints SciELO Preprints |
publisher.none.fl_str_mv |
SciELO Preprints SciELO Preprints SciELO Preprints |
dc.source.none.fl_str_mv |
reponame:SciELO Preprints instname:SciELO instacron:SCI |
instname_str |
SciELO |
instacron_str |
SCI |
institution |
SCI |
reponame_str |
SciELO Preprints |
collection |
SciELO Preprints |
repository.name.fl_str_mv |
SciELO Preprints - SciELO |
repository.mail.fl_str_mv |
scielo.submission@scielo.org |
_version_ |
1797047817895673856 |